Online citations, reference lists, and bibliographies.
← Back to Search

Improved High‐Performance Liquid Chromatography Assay For Atenolol In Plasma And Urine Using Fluorescence Detection

R. Morris, N. Saccoia, B. Sallustio, R. Zacest
Published 1991 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Summary An improved assay for racemic atenolol (AT) concentrations in human plasma and urine is described using a high-performance liquid chromatographic method with fluorescence detection. The method has a sensitivity limit of 0.5 μg/L in plasma with acceptable within- and between-run reproducibilities, and demonstrated linearity at concentrations up to 2,000 μg/L. A pilot clinical evaluation of the assay was undertaken on 56 trough plasma specimens from 36 outpatients on established AT therapy. Atenolol concentrations in these patients showed large variations at all prescribed doses, including undetectable levels in four patients (revealing unsuspected noncompliance). Because of its sensitivity and applicability to urinary analysis, the method can be used for pharmacokinetic studies and, under certain circumstances, may be valuable in clinical therapeutic drug monitoring.



This paper is referenced by
10.1093/chromsci/bms116
Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study.
M. Spanakis (2013)
10.1016/S0378-4347(96)00454-9
Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
F. Chiu (1997)
10.1016/S0378-4347(97)00298-3
Simultaneous determination of atenolol and chlorthalidone in plasma by high-performance liquid chromatography. Application to pharmacokinetic studies in man.
C. Giachetti (1997)
10.1016/S0378-4347(99)00518-6
Automated liquid chromatographic determination of atenolol in plasma using dialysis and trace enrichment on a cation-exchange precolumn for sample handling.
P. Chiap (2000)
10.1016/S0021-9673(01)00564-7
Determination of the β-blocker atenolol in plasma by capillary zone electrophoresis
R. Arias (2001)
10.1016/S0928-0987(99)00032-9
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
10.1093/chromsci/bms090
HPLC method for determination of atenolol in human plasma and application to a pharmacokinetic study in Turkey.
B. Yılmaz (2012)
10.1097/01.FTD.0000198647.39751.F5
A Micromethod for the Quantification of Atenolol in Plasma Using High-Performance Liquid Chromatography With Fluorescence Detection: Therapeutic Drug Monitoring of Two Patients With Severe Coronary Insufficiency Before Cardiac Surgery
F. D. Leite (2006)
10.1002/SSCP.201700023
Determination of atenolol in human urine by using HPLC
B. Yılmaz (2018)
10.1365/S10337-009-1325-3
GC–MS Determination of Atenolol Plasma Concentration after Derivatization with N-methyl-N-(trimethylsilyl)trifluoroacetamide
B. Yılmaz (2009)
10.1080/10826079708005838
Capillary Zone Electrophoretic Method for the Quantitative Determination of the β-Blocker Atenolol in Human Urine
M. I. Maguregui (1997)
10.1093/CHROMSCI/49.5.365
Determination of atenolol in human urine by gas chromatography-mass spectrometry method.
B. Yılmaz (2011)
10.1016/0378-4347(95)00303-3
High-performance liquid chromatography with amperometric detection applied to the screening of beta-blockers in human urine.
M. I. Maguregui (1995)
A Simple Method for the Quantification of Atenolol from the Forensic Human Blood and Visceral Samples by High Performance Thin Layer Chromatography
SK Krishnaraju (2020)
10.1093/CHROMSCI/36.10.516
Simultaneous Determination of the β-Blocker Atenolol and Several Complementary Antihypertensive Agents in Pharmaceutical Formulations and Urine by Capillary Zone Electrophoresis
M. I. Maguregui (1998)
Semantic Scholar Logo Some data provided by SemanticScholar